| pubmed-article:2836567 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2836567 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:2836567 | lifeskim:mentions | umls-concept:C0007276 | lld:lifeskim |
| pubmed-article:2836567 | lifeskim:mentions | umls-concept:C0007257 | lld:lifeskim |
| pubmed-article:2836567 | lifeskim:mentions | umls-concept:C1621958 | lld:lifeskim |
| pubmed-article:2836567 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:2836567 | pubmed:dateCreated | 1988-6-24 | lld:pubmed |
| pubmed-article:2836567 | pubmed:abstractText | High-dose 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) infusion into the internal carotid artery following cranial irradiation in the treatment of glioblastoma multiforme is accompanied by evidence of leukoencephalopathy in a significant number of patients. In an attempt to avoid this problem, a phase I trial was performed using intracarotid BCNU infusion before irradiation. Twenty-eight patients with grade III/III astrocytoma (World Health Organization Classification, equivalent to Kernohan grade IV) received a 400-mg infusion of BCNU into the infraophthalmic carotid artery. The treatment was repeated every 4 weeks for a total of four cycles prior to cranial irradiation (5500 to 6000 cGy). The major toxic sequelae included nausea and vomiting (24%), decreased visual acuity (14%), transient cerebral ischemia (3.5%), and thrombocytopenia (3.5%). Fatal leukoencephalopathy occurred in two patients. The median survival time was 37 weeks for all evaluable patients and 56+ weeks for those completing the protocol. The tumor response to drug infusion as judged by computerized tomography (CT) was complete in 22% of patients and partial in 22%; 56% showed no CT tumor response. Pre-irradiation intracarotid artery BCNU benefits a very small group of patients with grade III/III astrocytoma. The associated severe leukoencephalopathy makes this mode of therapy unacceptable for a phase III trial. | lld:pubmed |
| pubmed-article:2836567 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2836567 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2836567 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:2836567 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2836567 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2836567 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:2836567 | pubmed:issn | 0022-3085 | lld:pubmed |
| pubmed-article:2836567 | pubmed:author | pubmed-author:LinggoodR MRM | lld:pubmed |
| pubmed-article:2836567 | pubmed:author | pubmed-author:HochbergF HFH | lld:pubmed |
| pubmed-article:2836567 | pubmed:author | pubmed-author:BashirRR | lld:pubmed |
| pubmed-article:2836567 | pubmed:author | pubmed-author:HottlemanKK | lld:pubmed |
| pubmed-article:2836567 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2836567 | pubmed:volume | 68 | lld:pubmed |
| pubmed-article:2836567 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2836567 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2836567 | pubmed:pagination | 917-9 | lld:pubmed |
| pubmed-article:2836567 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2836567 | pubmed:meshHeading | pubmed-meshheading:2836567-... | lld:pubmed |
| pubmed-article:2836567 | pubmed:meshHeading | pubmed-meshheading:2836567-... | lld:pubmed |
| pubmed-article:2836567 | pubmed:meshHeading | pubmed-meshheading:2836567-... | lld:pubmed |
| pubmed-article:2836567 | pubmed:meshHeading | pubmed-meshheading:2836567-... | lld:pubmed |
| pubmed-article:2836567 | pubmed:meshHeading | pubmed-meshheading:2836567-... | lld:pubmed |
| pubmed-article:2836567 | pubmed:meshHeading | pubmed-meshheading:2836567-... | lld:pubmed |
| pubmed-article:2836567 | pubmed:meshHeading | pubmed-meshheading:2836567-... | lld:pubmed |
| pubmed-article:2836567 | pubmed:meshHeading | pubmed-meshheading:2836567-... | lld:pubmed |
| pubmed-article:2836567 | pubmed:meshHeading | pubmed-meshheading:2836567-... | lld:pubmed |
| pubmed-article:2836567 | pubmed:meshHeading | pubmed-meshheading:2836567-... | lld:pubmed |
| pubmed-article:2836567 | pubmed:meshHeading | pubmed-meshheading:2836567-... | lld:pubmed |
| pubmed-article:2836567 | pubmed:meshHeading | pubmed-meshheading:2836567-... | lld:pubmed |
| pubmed-article:2836567 | pubmed:meshHeading | pubmed-meshheading:2836567-... | lld:pubmed |
| pubmed-article:2836567 | pubmed:meshHeading | pubmed-meshheading:2836567-... | lld:pubmed |
| pubmed-article:2836567 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:2836567 | pubmed:articleTitle | Pre-irradiation internal carotid artery BCNU in treatment of glioblastoma multiforme. | lld:pubmed |
| pubmed-article:2836567 | pubmed:affiliation | Brain Tumor Center, Massachusetts General Hospital, Boston. | lld:pubmed |
| pubmed-article:2836567 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2836567 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2836567 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2836567 | lld:pubmed |
